Systems approach to neurodegenerative disease biomarker discovery

Annual Review of Pharmacology and Toxicology

Volumn 54, Issue , 2014, Pages 457-481

  Lausted, Christopher ^a   Lee, Inyoul ^a   Zhou, Yong ^a   Qin, Shizhen ^a   Sung, Jaeyun ^b   Price, Nathan D ^a   Hood, Leroy ^a   Wang, Kai ^a  

^a INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^b Asia Pacific Center for Theoretical Physics (APCTP)   (South Korea)

Author keywords

Animal models; MicroRNA; Next generation sequencing; Proteomics; Selected reaction monitoring; Systems biology

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; ARACHIDONIC ACID; BETA SECRETASE 1; BIOLOGICAL MARKER; CD14 ANTIGEN; CLUSTERIN; COPPER ZINC SUPEROXIDE DISMUTASE; DJ 1 PROTEIN; DOCOSAHEXAENOIC ACID; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; HUNTINGTIN; LIPID; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEIC ACID; PEPTIDE; PRESENILIN 1; PRESENILIN 2; PROTEIN; RNA; TAU PROTEIN;

ALZHEIMER DISEASE; BIOINFORMATICS; BIOTECHNOLOGY; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; DATA ANALYSIS; DEGENERATIVE DISEASE; DIAGNOSTIC TEST; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; HIGH THROUGHPUT SEQUENCING; HISTOPATHOLOGY; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; LABORATORY TEST; LIPID METABOLISM; LIPID PEROXIDATION; MASS SPECTROMETRY; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PARKINSON DISEASE; PLASMA; POSITRON EMISSION TOMOGRAPHY; PRION DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SALIVA; SERUM; STUDY DESIGN; SYSTEMIC DISEASE; SYSTEMS BIOLOGY; URINALYSIS; URINE;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; HUMANS; NEURODEGENERATIVE DISEASES; PROTEOMICS; SYSTEMS BIOLOGY;

EID: 84891873084     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-135928     Document Type: Review

References (148)

1. Frost B, Diamond MI. 2010. Prion-like mechanisms in neurodegenerative diseases. Nat. Rev. Neurosci. 11(3):155-59
2. de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, et al. 2012. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73(4):685-97. Erratum. 2012. Neuron 76(2):461
3. Hardy J, Revesz T. 2012. The spread of neurodegenerative disease. N. Engl. J. Med. 366:2126-28
4. Soto C. 2012. Transmissible proteins: expanding the prion heresy. Cell 149(5):968-77
5. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. 2012. De novo induction of amyloid-β deposition in vivo. Mol. Psychiatry 17(12):1347-53
6. Telling GC. 2013. The importance of prions. PLoS Pathog. 9(1):e1003090
7. Wu JW, Herman M, Liu L, Simoes S, Acker CM, et al. 2013. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J. Biol. Chem. 288(3):1856-70
8. Neumann M, Tolnay M, Mackenzie IR. 2009. The molecular basis of frontotemporal dementia. Expert Rev. Mol. Med. 11:e23
9. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, et al. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309(5733):476-81
10. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, et al. 2009. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. USA 106(47):20051-56
11. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, et al. 2012. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338(6109):949-53
12. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. 2009. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 11(2):219-25
13. Alzheimer's Assoc. 2012. 2012 Alzheimer's disease facts and figures. Alzheimer's Dement. 8(2):131-68
14. Barnes DE, Yaffe K. 2011. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 10(9):819-28
15. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A. 2009. Huntington's disease: the current state of research with peripheral tissues. Exp. Neurol. 219(2):385-97
16. Pfeiffera RF. 2003. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2(2):107-16
17. Hardoff R, Sula M, Tamir A, Soil A, Front A, et al. 2001. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov. Disord. 16(6):1041-47
18. Stack MJ, Vidal-Diez A, Arnold ME, Jones EM, Spencer YI, et al. 2011. Experimental bovine spongiform encephalopathy: detection of PrPSc in the small intestine relative to exposure dose and age. J. Comp. Pathol. 145(2-3):289-301
19. Schneider T, Moos V, Loddenkemper C, Marth T, Fenollar F, Raoult D. 2008. Whipple's disease: new aspects of pathogenesis and treatment. Lancet Infect. Dis. 8(3):179-90
20. Marth T. 2009. New insights into Whipple's disease-a rare intestinal inflammatory disorder. Dig. Dis. 27(4):494-501
21. Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, et al. 1997. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41(1):17-24
22. Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, et al. 2003. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 61(4):487-92
23. Logothetis NK. 2002. The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Philos. Trans. R. Soc. B 357(1424):1003-37
24. Bokde ALW, Lopez-Bayo P, Born C, Ewers M, Meindl T, et al. 2010. Alzheimer disease: functional abnormalities in the dorsal visual pathway. Radiology 254(1):219-26
25. 18F-FDG PET in patients with Alzheimer disease and controls. J. Nucl. Med. 53(6):902-7
26. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AMA. 2007. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 81(2):89-131
27. Politis M, Su P, Piccini P. 2012. Imaging of microglia in patients with neurodegenerative disorders. Front. Pharmacol. 3:96
28. O'Brien JT. 2007. Role of imaging techniques in the diagnosis of dementia. Br. J. Radiol. 80(Spec. Issue 2):S71-77
29. Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, et al. 2013. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology 266(2):583-91
30. Zhang Y, Londos E, Minthon L, Wattmo C, Liu H, et al. 2008. Usefulness of computed tomography linear measurements in diagnosing Alzheimer's disease. Acta Radiol. 49(1):91-97
31. Schoonenboom NS, van der Flier WM, Blankenstein MA, Bouwman FH, Van Kamp GJ, et al. 2008. CSF and MRImarkers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol. Aging 29(5):669-75
32. Park KW, Kim HS, Cheon SM, Cha JK, Kim SH, Kim JW. 2011. Dementia with Lewy bodies versus Alzheimer's disease and Parkinson's disease dementia: a comparison of cognitive profiles. J. Clin. Neurol. 7(1):19-24
33. Tröster AI. 2008. Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for "mild cognitive impairment" and biomarkers. Neuropsychol. Rev. 18(1):103-19
34. Etheridge A, Lee I, Hood L, Galas D, Wang K. 2011. Extracellular microRNA: a new source of biomarkers. Mutat. Res. 717(1-2):85-90
35. Irwin DJ, Trojanowski JQ, Grossman M. 2013. Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Front. Aging Neurosci. 5:6
36. Constantinescu R, Mondello S. 2012. Cerebrospinal fluid biomarker candidates for Parkinsonian disorders. Front. Neurol. 3:187
37. Choi YS, Choe LH, Lee KH. 2010. Recent cerebrospinal fluid biomarker studies of Alzheimer's disease. Expert Rev. Proteomics 7(6):919-29
38. Alexandrov PN, Dua P, Hill JM, Bhattacharjee S, Zhao Y, Lukiw WJ. 2012. microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int. J. Biochem. Mol. Biol. 3(4):365-73
39. Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF III, Liotta LA. 2005. CSF proteome: a protein repository for potential biomarker identification. Expert Rev. Proteomics 2(1):57-70
40. Zhang J. 2007. Proteomics of human cerebrospinal fluid-the good, the bad, and the ugly. Proteomics Clin. Appl. 1(8):805-19
41. Välk K, Vooder T, Kolde R, Reintam MA, Petzold C, et al. 2010. Gene expression profiles of non-small cell lung cancer: survival prediction and new biomarkers. Oncology 79(3-4):283-92
42. Hollander Z, Lin D, Chen V, Ng R, Wilson-McManus J, et al. 2010. Whole blood biomarkers of acute cardiac allograft rejection: double-crossing the biopsy. Transplantation 90(12):1388-93
43. Bai VU, Hwang O, Divine GW, Barrack ER, Menon M, et al. 2012. Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer. PLoS ONE 7(4):e34875
44. Guipaud O. 2013. Serum and plasma proteomics and its possible use as detector and predictor of radiation diseases. Adv. Exp. Med. Biol. 990:61-86
45. Lottspeich F, Kellermann J, Keidel EM. 2010. Molecular biology tools: proteomics techniques in biomarker discovery. Scand. J. Clin. Lab. Investig. Suppl. 242:19-22
46. Fanayan S, Hincapie M, Hancock WS. 2012. Using lectins to harvest the plasma/serum glycoproteome. Electrophoresis 33(12):1746-54
47. Lee JY, Kim JY, Park GW, Cheon MH, Kwon KH, et al. 2011. Targeted mass spectrometric approach for biomarker discovery and validation with nonglycosylated tryptic peptides from N-linked glycoproteins in human plasma. Mol. Cell. Proteomics 10(12):M111.009290
48. Mortezai N, Harder S, Schnabel C, Moors E, Gauly M, et al. 2010. Tandem affinity depletion: a combination of affinity fractionation and immunoaffinity depletion allows the detection of low-abundance components in the complex proteomes of body fluids. J. Proteome Res. 9(12):6126-34
49. Tan SH, Mohamedali A, Kapur A, Baker MS. 2013. Ultradepletion of human plasma using chicken antibodies: a proof of concept study. J. Proteome Res. 12(6):2399-413
50. Polaskova V, Kapur A, Khan A, Molloy MP, Baker MS. 2010. High-abundance protein depletion: comparison of methods for human plasma biomarker discovery. Electrophoresis 31(3):471-82
51. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, et al. 2002. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis. 9(2):244-48
52. Sato S, Mizuno Y, Hattori N. 2005. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64(6):1081-83
53. de la Monte SM, Wands JR. 2002. The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer's disease. Front. Biosci. 7:d989-96
54. Conrad C, Vianna C, Freeman M, Davies P. 2002. A polymorphic gene nested within an intron of the tau gene: implications for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 99(11):7751-56
55. Oh YS, Turner RJ. 2006. Effect of γ-secretase inhibitors on muscarinic receptor-mediated calcium signaling in human salivary epithelial cells. Am. J. Physiol. Cell Physiol. 291(1):C76-82
56. Chiappin S, Antonelli G, Gatti R, De Palo EF. 2007. Saliva specimen: a new laboratory tool for diagnostic and basic investigation. Clin. Chim. Acta 383(1-2):30-40
57. Hackam DG, Redelmeier DA. 2006. Translation of research evidence from animals to humans. JAMA 296(14):1731-32
58. Tsilidis KK, Panagiotou OA, Sena ES, Aretouli E, Evangelou E, et al. 2013. Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol. 11(7):e1001609
59. Mineur YS, McLoughlin D, Crusio WE, Sluyter F. 2005. Genetic mouse models of Alzheimer's disease. Neural Plast. 12(4):299-310
60. Lee MK, Stirling W, Xu Y, Xu X, Qui D, et al. 2002. Humanα- synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 99(13):8968-73
61. Harvey BK, Wang Y, Hoffer BJ. 2008. Transgenic rodent models of Parkinson's disease. Acta Neurochir. Suppl. 101:89-92
62. Huntington's Dis. Collab. Res. Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72(6):971-83
63. Collinge J, Palmer MS, Sidle KC, Hill AF, Gowland I, et al. 1995. Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature 378(6559):779-83. Erratum. 1997. Nature 389(6650):526
64. Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, et al. 1995. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83(1):79-90
65. Stephenson DA, Chiotti K, Ebeling C, Groth D, DeArmond SJ, et al. 2000. Quantitative trait loci affecting prion incubation time in mice. Genomics 69(1):47-53
66. Hwang D, Lee IY, Yoo H, Gehlenborg N, Cho JH, et al. 2009. A systems approach to prion disease. Mol. Syst. Biol. 5:252
67. Prusiner SB, Groth D, Serban A, Koehler R, Foster D, et al. 1993. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc. Natl. Acad. Sci. USA 90(22):10608-12
68. Büeler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, et al. 1993. Mice devoid of PrP are resistant to scrapie. Cell 73(7):1339-47
69. Hu S, Jiang J, Wong DT. 2010. Proteomic analysis of saliva: 2D gel electrophoresis, LC-MS/MS, and Western blotting. Methods Mol. Biol. 666:31-41
70. Baumann M, Meri S. 2004. Techniques for studying protein heterogeneity and post-translational modifications. Expert Rev. Proteomics 1(2):207-17
71. Gygi SP, Corthals GL, Zhang Y, Rochon Y, Aebersold R. 2000. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc. Natl. Acad. Sci. USA 97(17):9390-95
72. Surinova S, Schiess R, Huttenhain R, Cerciello F, Wollscheid B, Aebersold R. 2011. On the development of plasma protein biomarkers. J. Proteome Res. 10(1):5-16
73. Evans C, Noirel J, Ow SY, Salim M, Pereira-Medrano AG, et al. 2012. An insight into iTRAQ:Where do we stand now? Anal. Bioanal. Chem. 404(4):1011-27
74. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, et al. 2002. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1(5):376-86
75. Gillet LC, Navarro P, Tate S, Röst H, Selevsek N, et al. 2012. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell. Proteomics 11(6):O111-016717
76. Xu Y, Komiyama M. 2012. Structure, function and targeting of human telomere RNA. Methods 57(1): 100-5
77. Scott WG, Martick M, Chi YI. 2009. Structure and function of regulatory RNA elements: ribozymes that regulate gene expression. Biochim. Biophys. Acta 1789(9-10):634-41
78. Werner A, Sayer JA. 2009. Naturally occurring antisense RNA: function and mechanisms of action. Curr. Opin. Nephrol. Hypertens. 18(4):343-49
79. Montange RK, Batey RT. 2008. Riboswitches: emerging themes in RNA structure and function. Annu. Rev. Biophys. 37:117-33
80. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, et al. 2009. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. USA 106(11):4402-7
81. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 105(30):10513-18
82. Gidlöf O, Andersson P, van der Pals J, Götberg M, Erlinge D. 2011. Cardiospecific microRNA plasma levels correlatewith troponin and cardiac function in patients withSTelevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology 118(4):217-26
83. Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, et al. 2011. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ. Cardiovasc. Genet. 4(4):446-54
84. Wang K, Yuan Y, Li H, Cho JH, Huang D, et al. 2013. The spectrum of circulating RNA: a window into systems toxicology. Toxicol. Sci. 132(2):478-92
85. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. 2012. Comparing the microRNA spectrum between serum and plasma. PLoS ONE 7(7):e41561
86. Ishikawa M, Tajima Y, Murayama M, Senoo Y, Maekawa K, Saito Y. 2013. Plasma and serum from nonfasting men and women differ in their lipidomic profiles. Biol. Pharm. Bull. 36(4):682-85
87. Frank EA, Shubha MC, D'Souza CJ. 2012. Blood glucose determination: plasma or serum? J. Clin. Lab. Anal. 26(5):317-20
88. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, et al. 2010. The microRNA spectrum in 12 body fluids. Clin. Chem. 56(11):1733-41
89. Callari M, Dugo M, Musella V, Marchesi E, Chiorino G, et al. 2012. Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues. PLoS ONE 7(9):e45105
90. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, et al. 1999. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 402(6761):537-40
91. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, et al. 2010. Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science 330(6012):1774
92. Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, et al. 2012. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol. 124(1):23-35
93. Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, et al. 2010. Plasma amyloid-β as a biomarker in Alzheimer's disease: the AIBL study of aging. J. Alzheimer's Dis. 20(4):1233-42
94. Huang Y, Potter R, Sigurdson W, Kasten T, Connors R, et al. 2012. β-Amyloid dynamics in human plasma. Arch Neurol. 69(12):1591-97
95. Banks WA, Robinson SM, Verma S, Morley JE. 2003. Efflux of human and mouse amyloid βproteins 1-40 and 1-42 from brain: impairment in amousemodel of Alzheimer's disease. Neuroscience 121(2):487-92
96. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, et al. 2008. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch. Neurol. 65(8):1102-7
97. Hampel H, Shen Y. 2009. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. Scand. J. Clin. Lab. Investig. 69(1):8-12
98. Schraen-Maschke S, Sergeant N, Dhaenens CM, Bombois S, Deramecourt V, et al. 2008. Tau as a biomarker of neurodegenerative diseases. Biomark. Med. 2(4):363-84
99. Andreasen N, Sjogren M, Blennow K. 2003. CSFmarkers for Alzheimer's disease: total tau, phospho-tau and Aβ42. World J. Biol. Psychiatry 4(4):147-55
100. Ost M, Nylén K, Csajbok L, Ohrfelt AO, Tullberg M, et al. 2006. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67(9):1600-4
101. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, et al. 2003. α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17(13):1945-47
102. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, et al. 2006. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349(1):162-66
103. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. 2011.α-Synuclein and tau concentrations in cerebrospinal fluid of patients presentingwith parkinsonism: a cohort study. Lancet Neurol. 10(3):230-40
104. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, et al. 2010. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133(Pt. 3):713-26
105. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, et al. 2011. Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J. 25(1):326-36
106. Zhang W, Wang T, Pei Z, Miller DS, Wu X, et al. 2005. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19(6):533-42
107. Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B. 2009. Seeding induced by α-synuclein oligomers provides evidence for spreading of α-synuclein pathology. J. Neurochem. 111(1):192-203
108. Esiri MM. 2007. The interplay between inflammation and neurodegeneration in CNS disease. J. Neuroimmunol. 184(1-2):4-16
109. Cameron B, Landreth GE. 2010. Inflammation, microglia, and Alzheimer's disease. Neurobiol. Dis. 37(3):503-9
110. Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, et al. 2011. Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromol. Med. 13(2):151-59
111. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, et al. 2010. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol. Psychiatry 68(10):903-12
112. Corrêa JD, Starling D, Teixeira AL, Caramelli P, Silva TA. 2011. Chemokines in CSF of Alzheimer's disease patients. Arq. Neuropsiquiatr. 69(3):455-59
113. Yin GN, Jeon H, Lee S, Lee HW, Cho JY, Suk K. 2009. Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. J. Neurosci. Res. 87(11):2578-90
114. Landreth GE, Reed-Geaghan EG. 2009. Toll-like receptors in Alzheimer's disease. Curr. Top. Microbiol. Immunol. 336:137-53
115. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, et al. 2007. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 6(7):2833-40
116. Gulesserian T, Seidl R, Hardmeier R, Cairns N, Lubec G. 2001. Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2is overexpressed in brains of patients with Down syndrome. J. Investig. Med. 49(1):41-46
117. Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C. 2009. The genetics of Parkinson's syndromes: a critical review. Curr. Opin. Genet. Dev. 19(3):254-65
118. Waragai M, Wei J, Fujita M, Nakai M, Ho GJ, et al. 2006. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem. Biophys. Res. Commun. 345(3):967-72
119. Waragai M, Nakai M, Wei J, Fujita M, Mizuno H, et al. 2007. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci. Lett. 425(1):18-22
120. Maita C, Tsuji S, Yabe I, Hamada S, Ogata A, et al. 2008. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci. Lett. 431(1):86-89
121. Kálmán J, Kitajka K, Pákáski M, Zvara A, Juhász A, et al. 2005. Gene expression profile analysis of lymphocytes from Alzheimer's patients. Psychiatr. Genet. 15(1):1-6
122. Chen KD, Chang PT, Ping YH, Lee HC, Yeh CW, Wang PN. 2011. Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer's disease. Neurobiol. Dis. 43(3):698-705
123. Kester MI, van der Flier WM, Visser A, Blankenstein MA, Scheltens P, Oudejans CB. 2011. Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. Clin. Chem. Lab. Med. 50(1):61-65
124. Villa C, Ridolfi E, Fenoglio C, Ghezzi L, Vimercati R, et al. 2013. Expression of the transcription factor Sp1 and its regulatory hsa-miR-29b in peripheral blood mononuclear cells from patients with Alzheimer's disease. J. Alzheimer's Dis. 35(3):487-94
125. Zhang W, Wang LZ, Yu JT, Chi ZF, Tan L. 2012. Increased expressions of TLR2 and TLR4 on peripheral blood mononuclear cells from patients with Alzheimer's disease. J. Neurol. Sci. 315(1-2):67-71
126. Coppola G, Karydas A, Rademakers R, Wang Q, Baker M, et al. 2008. Gene expression study on peripheral blood identifies progranulin mutations. Ann. Neurol. 64(1):92-96
127. Rye PD, Booij BB, Grave G, Lindahl T, Kristiansen L, et al. 2011. A novel blood test for the early detection of Alzheimer's disease. J. Alzheimer's Dis. 23(1):121-29
128. Fehlbaum-Beurdeley P, Sol O, DésiréL, Touchon J, Dantoine T, et al. 2012. Validation of Aclarus Dx TM, a blood-based transcriptomic signature for the diagnosis of Alzheimer's disease. J. Alzheimer's Dis. 32(1):169-81
129. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, et al. 2007. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl. Acad. Sci. USA 104(3):955-60
130. Soreq L, Bergman H, Israel Z, Soreq H. 2012. Exon arrays reveal alternative splicing aberrations in Parkinson's disease leukocytes. Neurodegener. Dis. 10(1-4):203-6
131. Mutez E, Leprêtre F, Le Rhun E, Larvor L, Duflot A, et al. 2011. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. Hum. Mutat. 32(4):E2079-90
132. Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, et al. 2012. A molecular signature in blood identifies early Parkinson's disease. Mol. Neurodegener. 7:26
133. Delay C, Mandemakers W, Hébert SS. 2012. MicroRNAs in Alzheimer's disease. Neurobiol. Dis. 46(2):285-90
134. Hébert SS, De Strooper B. 2009. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 32(4):199-206
135. Sheinerman KS, Tsivinsky VG, Crawford F, Mullan MJ, Abdullah L, Umansky SR. 2012. Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging 4(9):590-605
136. Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, Björkqvist M. 2011. Hsa-miR-34b is a plasmastable microRNA that is elevated in pre-manifestHuntington's disease. Hum. Mol. Genet. 20(11):2225-37
137. Ai J, Sun LH, Che H, Zhang R, Zhang TZ, et al. 2013. MicroRNA-195 protects against dementia induced by chronic brain hypoperfusion via its anti-amyloidogenic effect in rats. J. Neurosci. 33(9):3989-4001
138. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, et al. 2008. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimer's Dis. 14(1):27-41
139. Khoo SK, Petillo D, Kang UJ, Resau JH, Berryhill B, et al. 2012. Plasma-based circulating microRNA biomarkers for Parkinson's disease. J. Parkinson's Dis. 2:321-31
140. Margis R, Margis R, Rieder CR. 2011. Identification of blood microRNAs associated to Parkinson's disease. J. Biotechnol. 152(3):96-101
141. Geekiyanage H, Jicha GA, Nelson PT, Chan C. 2012. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp. Neurol. 235(2):491-96
142. Xu XH, Huang Y, Wang G, Chen SD. 2012. Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease. Neurosci. Bull. 28(5):641-48
143. Inst. Med. Natl. Acad. 2012. Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC: Natl. Acad. Press
144. Qin S, Zhou Y, Lok AS, Tsodikov A, Yan X, et al. 2012. SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics 12(8):1244-52
145. Ko Y, Ament SA, Eddy JA, Caballero J, Earls JC, et al. 2013. Cell type-specific genes show striking and distinct patterns of spatial expression in the mouse brain. Proc. Natl. Acad. Sci. USA 110(8):3095-100
146. Hüttenhain R, Surinova S, Ossola R, Sun Z, Campbell D, et al. 2013. N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications. Mol. Cell. Proteomics 12(4):1005-16
147. Li XJ, Hayward C, Fong PY, Dominguez M, Hunsucker SW, et al. 2013. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci. Transl. Med. 5(207):207ra142
148. Hood L, Flores M. 2012. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N. Biotechnol. 29(6):613-24